# FDA Drug Shortage Watch

Fetched: 2026-04-26T00:12:38+00:00
Source: https://api.fda.gov/drug/shortages.json

This report is an automated public-data summary only. It is not medical, legal, clinical, purchasing, sourcing, or inventory advice. No professional review is claimed.
FormularySignal is not affiliated with, endorsed by, sponsored by, or approved by FDA.
Change score is an operational sorting label based on public-record status, reason, category, and recency. It is not a medical-importance rating, clinical severity rating, procurement instruction, or inventory signal.
Each row includes a source query URL in CSV/JSON outputs; verify important records at FDA/openFDA before acting.

## Snapshot

- Total records: 1683
- Status counts: {"Current": 1147, "Resolved": 29, "To Be Discontinued": 507}
- Diff counts: {"changed": 0, "new": 0, "removed": 0, "status_changed": 0}

## Top Categories

- Psychiatry: 245
- Anesthesia: 225
- Cardiovascular: 202
- Analgesia/Addiction: 131
- Anti-Infective: 84
- Oncology: 73
- Anesthesia; Pediatric: 69
- Endocrinology/Metabolism: 63
- Endocrinology/Metabolism; Gastroenterology; Other; Pediatric: 53
- Neurology: 52
- Neurology; Pediatric; Psychiatry: 40
- Rheumatology: 38

## Highest Change-Score Drug-Level Signals

- [high, 80] Carboplatin Injection (29 records, 8 companies, statuses {"Current": 27, "To Be Discontinued": 2}, updated 2026-04-24): Demand increase for the drug (9), reason not specified (8). Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Carboplatin+Injection%22+AND+company_name%3A%22Accord+Healthcare+Inc.%22+AND+package_ndc%3A%2216729-295-33%22
- [high, 80] Dexamethasone Sodium Phosphate Injection (16 records, 5 companies, statuses {"Current": 16}, updated 2026-04-23): reason not specified (13), Demand increase for the drug (3). Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Dexamethasone+Sodium+Phosphate+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-165-30%22
- [high, 80] Methotrexate Sodium Injection (14 records, 5 companies, statuses {"Current": 14}, updated 2026-04-23): reason not specified (10), Other (2). Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Methotrexate+Sodium+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%2261703-124-40%22
- [high, 78] Lidocaine Hydrochloride Injection (70 records, 10 companies, statuses {"Current": 68, "To Be Discontinued": 2}, updated 2026-04-23): reason not specified (55), Demand increase for the drug (10). Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Lidocaine+Hydrochloride+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-486-27%22
- [high, 78] Dexmedetomidine Hydrochloride Injection (53 records, 14 companies, statuses {"Current": 52, "To Be Discontinued": 1}, updated 2026-04-24): reason not specified (44), Other (3). Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Dexmedetomidine+Hydrochloride+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-671-50%22
- [high, 78] Ropivacaine Hydrochloride Injection (46 records, 5 companies, statuses {"Current": 46}, updated 2026-04-23): reason not specified (32), Demand increase for the drug (5). Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Ropivacaine+Hydrochloride+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-288-11%22
- [high, 78] Bupivacaine Hydrochloride Injection (42 records, 6 companies, statuses {"Current": 42}, updated 2026-04-23): reason not specified (36), Other (3). Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Bupivacaine+Hydrochloride+Injection%22+AND+company_name%3A%22Kindos+Pharmaceuticals+Co.+Ltd.%22+AND+package_ndc%3A%2271288-723-52%22
- [high, 78] Midazolam Hydrochloride Injection (30 records, 6 companies, statuses {"Current": 30}, updated 2026-04-23): reason not specified (14), Demand increase for the drug (8). Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Midazolam+Hydrochloride+Injection%22+AND+company_name%3A%22Gland+Pharma+Limited%22+AND+package_ndc%3A%2270860-601-05%22
- [high, 78] Rocuronium Bromide Injection (26 records, 11 companies, statuses {"Current": 26}, updated 2026-04-24): reason not specified (20), Demand increase for the drug (5). Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Rocuronium+Bromide+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%220409-1403-10%22
- [high, 78] Clindamycin Phosphate Injection (20 records, 4 companies, statuses {"Current": 20}, updated 2026-04-24): reason not specified (10), Other (6). Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Clindamycin+Phosphate+Injection%22+AND+company_name%3A%22Sandoz+Inc.%22+AND+package_ndc%3A%220781-3290-09%22
- [high, 76] Atropine Sulfate Injection (18 records, 7 companies, statuses {"Current": 16, "To Be Discontinued": 2}, updated 2026-04-23): reason not specified (10), Discontinuation of the manufacture of the drug (4). Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Atropine+Sulfate+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%220409-4910-34%22
- [high, 76] Bumetanide Injection (12 records, 5 companies, statuses {"Current": 12}, updated 2026-04-23): reason not specified (9), Demand increase for the drug (3). Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Bumetanide+Injection%22+AND+company_name%3A%22Sagent+Pharmaceuticals%22+AND+package_ndc%3A%2225021-321-10%22
- [high, 74] Furosemide Injection (33 records, 9 companies, statuses {"Current": 33}, updated 2026-04-24): reason not specified (18), Other (7). Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Furosemide+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-280-10%22
- [high, 74] Heparin Sodium Injection (10 records, 4 companies, statuses {"Current": 9, "To Be Discontinued": 1}, updated 2026-04-23): reason not specified (5), Requirements related to complying with good manufacturing practices (2). Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Heparin+Sodium+Injection%22+AND+company_name%3A%22Baxter+Healthcare%22+AND+package_ndc%3A%220338-0431-03%22
- [high, 73] Azacitidine Injection (9 records, 9 companies, statuses {"Current": 9}, updated 2026-04-20): reason not specified (7), Other (1). Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Azacitidine+Injection%22+AND+company_name%3A%22Meitheal+Pharmaceuticals%2C+Inc.%22+AND+package_ndc%3A%2271288-115-30%22
- [high, 73] Rifampin Capsule (9 records, 2 companies, statuses {"Current": 9}, updated 2026-04-20): Discontinuation of the manufacture of the drug (4), Shortage of an active ingredient (3). Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Rifampin+Capsule%22+AND+company_name%3A%22Lupin+Pharmaceuticals%2C+Inc.%22+AND+package_ndc%3A%2268180-658-06%22
- [high, 73] Rifampin Injection (4 records, 3 companies, statuses {"Current": 3, "To Be Discontinued": 1}, updated 2026-04-23): reason not specified (3), Discontinuation of the manufacture of the drug (1). Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Rifampin+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-351-20%22
- [high, 72] Fentanyl Citrate Injection (19 records, 3 companies, statuses {"Current": 19}, updated 2026-04-23): reason not specified (8), Other (8). Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Fentanyl+Citrate+Injection%22+AND+company_name%3A%22Hikma+Pharmaceuticals+USA%2C+Inc.%22+AND+package_ndc%3A%220641-6029-25%22
- [high, 72] Metronidazole Injection (4 records, 3 companies, statuses {"Current": 4}, updated 2026-04-20): reason not specified (2), Other (1). Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Metronidazole+Injection%22+AND+company_name%3A%22InfoRLife+SA%22+AND+package_ndc%3A%220409-0152-24%22
- [high, 71] Etomidate Injection (19 records, 6 companies, statuses {"Current": 19}, updated 2026-04-24): reason not specified (17), Demand increase for the drug (2). Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Etomidate+Injection%22+AND+company_name%3A%22Caplin+Steriles%2C+Ltd.%22+AND+package_ndc%3A%2272485-508-10%22

## Highest Change-Score Presentation Records

- [high, 80] Carboplatin Injection / Hospira, Inc., a Pfizer Company (Oncology; Injection; Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18); NDC 61703-339-18; updated 2026-04-22): Demand increase for the drug. Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Carboplatin+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%2261703-339-18%22
- [high, 80] Carboplatin Injection / Hospira, Inc., a Pfizer Company (Oncology; Injection; Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05); NDC 61703-262-05; updated 2026-04-22): Demand increase for the drug. Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Carboplatin+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%2261703-262-05%22
- [high, 80] Carboplatin Injection / Hospira, Inc., a Pfizer Company (Oncology; Injection; Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50); NDC 61703-339-50; updated 2026-04-22): Demand increase for the drug. Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Carboplatin+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%2261703-339-50%22
- [high, 80] Methotrexate Sodium Injection / Fresenius Kabi USA, LLC (Rheumatology; Oncology; Injection; Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10); NDC 63323-123-10; updated 2026-04-23): Demand increase for the drug. Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Methotrexate+Sodium+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-123-10%22
- [high, 80] Dexamethasone Sodium Phosphate Injection / Fresenius Kabi USA, LLC (Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology; Injection; Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10); NDC 63323-516-10; updated 2026-04-23): Demand increase for the drug. Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Dexamethasone+Sodium+Phosphate+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2263323-516-10%22
- [high, 80] Carboplatin Injection / Gland Pharma Limited (Oncology; Injection; Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01); NDC 54288-166-01; updated 2026-04-24): Demand increase for the drug. Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Carboplatin+Injection%22+AND+company_name%3A%22Gland+Pharma+Limited%22+AND+package_ndc%3A%2254288-166-01%22
- [high, 80] Carboplatin Injection / Hospira, Inc., a Pfizer Company (Oncology; Injection; Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22); NDC 61703-339-22; updated 2026-04-22): Demand increase for the drug. Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Carboplatin+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%2261703-339-22%22
- [high, 80] Carboplatin Injection / Gland Pharma Limited (Oncology; Injection; Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01); NDC 54288-165-01; updated 2026-04-24): Demand increase for the drug. Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Carboplatin+Injection%22+AND+company_name%3A%22Gland+Pharma+Limited%22+AND+package_ndc%3A%2254288-165-01%22
- [high, 80] Carboplatin Injection / Hospira, Inc., a Pfizer Company (Oncology; Injection; Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05); NDC 61703-600-05; updated 2026-04-22): Demand increase for the drug. Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Carboplatin+Injection%22+AND+company_name%3A%22Hospira%2C+Inc.%2C+a+Pfizer+Company%22+AND+package_ndc%3A%2261703-600-05%22
- [high, 80] Dexamethasone Sodium Phosphate Injection / Fresenius Kabi USA, LLC (Dermatology; Endocrinology/Metabolism; Gastroenterology; Hematology; Neurology; Oncology; Ophthalmology; Other; Pulmonary/Allergy; Rheumatology; Injection; Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-106-10); NDC 76045-106-10; updated 2026-04-23): Demand increase for the drug. Source query: https://api.fda.gov/drug/shortages.json?search=generic_name%3A%22Dexamethasone+Sodium+Phosphate+Injection%22+AND+company_name%3A%22Fresenius+Kabi+USA%2C+LLC%22+AND+package_ndc%3A%2276045-106-10%22